Mode of Actions of Bile Acids in Avoidance of Colorectal Cancer Development; and their Therapeutic Applications in Cancers - A Narrative Review

Q3 Pharmacology, Toxicology and Pharmaceutics Journal of Pharmacy and Nutrition Sciences Pub Date : 2022-12-13 DOI:10.29169/1927-5951.2022.12.04

K. Kaur, G. N. K. Allahbadia, M. Singh

{"title":"Mode of Actions of Bile Acids in Avoidance of Colorectal Cancer Development; and their Therapeutic Applications in Cancers - A Narrative Review","authors":"K. Kaur, G. N. K. Allahbadia, M. Singh","doi":"10.29169/1927-5951.2022.12.04","DOIUrl":null,"url":null,"abstract":"Bile Acids (BAs) possess a considerably significant part in the form of emulsifiers in digestion besides absorption of dietary lipids. BAs represent amphiphilic molecules, that are primary metabolites formed from cholesterol by the aid of enzymes acting on cholesterol. Earlier BAs were believed to be tumor repressors. The tumor repressive actions of BAs are correlated with programmed cell death (PCD). Furthermore, dependent on this observation different Synthetic BAs products have been generated along with their utilization regarding induction of PCD (in the form of apoptosis, autophagy or necroptosis in variable kinds of human cancers. Thus we conducted a narrative review till August 2022. The present article might form the basis of generationof such innovative therapies even for cancers/tumors that are cisplatin resistant. With time these therapies might be used for the treatment of neurodegenerative diseases (NDD), amyotrophic sclerosis, and numerous metabolic and haematological diseases as described for use of TUDCA.","PeriodicalId":16959,"journal":{"name":"Journal of Pharmacy and Nutrition Sciences","volume":"55 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacy and Nutrition Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29169/1927-5951.2022.12.04","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Bile Acids (BAs) possess a considerably significant part in the form of emulsifiers in digestion besides absorption of dietary lipids. BAs represent amphiphilic molecules, that are primary metabolites formed from cholesterol by the aid of enzymes acting on cholesterol. Earlier BAs were believed to be tumor repressors. The tumor repressive actions of BAs are correlated with programmed cell death (PCD). Furthermore, dependent on this observation different Synthetic BAs products have been generated along with their utilization regarding induction of PCD (in the form of apoptosis, autophagy or necroptosis in variable kinds of human cancers. Thus we conducted a narrative review till August 2022. The present article might form the basis of generationof such innovative therapies even for cancers/tumors that are cisplatin resistant. With time these therapies might be used for the treatment of neurodegenerative diseases (NDD), amyotrophic sclerosis, and numerous metabolic and haematological diseases as described for use of TUDCA.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

胆汁酸在预防结直肠癌发生中的作用模式及其在癌症治疗中的应用综述

胆汁酸在消化过程中除了吸收膳食脂肪外，还以乳化剂的形式起着相当重要的作用。BAs代表两亲性分子，是由胆固醇在酶作用下形成的初级代谢产物。早期的BAs被认为是肿瘤抑制因子。BAs的肿瘤抑制作用与程序性细胞死亡(PCD)有关。此外，根据这一观察，已经产生了不同的合成BAs产品，并将其用于诱导各种人类癌症的PCD(以细胞凋亡、自噬或坏死的形式)。因此，我们进行了一次叙事回顾，直到2022年8月。这篇文章可能会形成这种创新疗法的基础，甚至是针对顺铂耐药的癌症/肿瘤。随着时间的推移，这些疗法可能用于治疗神经退行性疾病(NDD)、肌萎缩性硬化症和许多代谢和血液系统疾病，这些疾病被描述为使用TUDCA。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Pharmacy and Nutrition Sciences Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)

自引率

0.00%

发文量